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Osteoarthritis (OA) is a complex disease of the skeleton and is associated with aging. Both environmental and
genetic factors contribute to its pathogenesis. We set out to identify novel genes associated with OA, concentrating
on regulatory polymorphisms allowing for differential expression. Our strategy to identify differentially expressed
genes included an initial transcriptome analysis of the peripheral blood mononuclear cells of six patients with OA
and six age-matched healthy controls. These were screened for allelic expression imbalances and potentially reg-
ulatory single-nucleotide polymorphisms (SNPs) in the 5′ regions of the genes. To establish disease association,
disparate promoter SNP distributions correlating with the differential expression were tested on larger cohorts.
Our approach yielded 26 candidate genes differentially expressed between patients and controls. Whereas BLP2
and CIAS1 seem to be trans-regulated, as the absence of allelic expression imbalances suggests, the presence of
allelic imbalances confirms cis-regulatory mechanisms for RHOB and TXNDC3. Interestingly, on/off–switching
suggests additional trans-regulation for TXNDC3. Moreover, we demonstrate for RHOB and TXNDC3 statistically
significant associations between 5′ SNPs and the disease that hint at regulatory functions. Investigating the respective
genes functionally will not only shed light on the disease association but will also add to the understanding of the
pathogenic processes involved in OA and may point out novel therapeutic approaches.
Received September 12, 2005; accepted for publication March 1, 2006; electronically published March 22, 2006.
Address for correspondence and reprints: Dr. Sandra Mahr, Institute for Immunology, Medical Faculty, Schillingallee 70, 18055 Rostock,
Germany. E-mail: sandra.mahr@med.uni-rostock.de
Am. J. Hum. Genet. 2006;78:793–803.  2006 by The American Society of Human Genetics. All rights reserved. 0002-9297/2006/7805-0007$15.00
Osteoarthritis (OA [MIM 165720]) is the most common
musculoskeletal disease associated with aging.1 Clinical
problems include pain and joint stiffness, which often
lead to significant disability and joint replacement. Al-
though OA has previously been considered a mere con-
sequence of age-related cartilage degeneration, it is now
accepted that OA is the result of active disease processes.
Imbalances between the synthesis and degradation of the
extracellular matrix and between the proliferation and
apoptosis of the articular chondrocytes are the most
widely discussed disease processes.2–5
OA is a complex disease with multiple environmental
and genetic factors contributing to its pathogenesis.6–9
To elucidate the genetics, whole-genome linkage analyses
and candidate-gene approaches have been performed.9
Whereas the former may provide large QTLs without
revealing the disease-associated genes themselves, the
latter can yield only small aspects of the genetics.10–15
The description of differential gene expression as a
driving force in evolution led to an increased appreci-
ation of regulatory gene polymorphisms.16 Although the
differential expression of genes allows for a flexible re-
sponse to a changing environment and, thus, may be
beneficial for the population as a whole, adverse effects
for the individual may occur. Indeed, regulatory gene
polymorphisms are likely candidates for an association
with complex diseases: moderate alterations in gene ex-
pression can implement subtle differences over a long
period of time and may render the organism susceptible
to cumulative pathogenic impacts.17 In OA, regulatory
gene polymorphisms within the IL1 locus have been de-
scribed elsewhere to be associated with the disease.18,19
We set out to identify novel regulatory gene poly-
morphisms associated with OA. To that end, we per-
formed transcriptome analyses of peripheral blood
mononuclear cells (PBMC) from OA patients and con-
trols, and we identified genes that were differentially
expressed. We based our study on the assumption that
regulatory SNPs leading to differential expression in
PBMC may do so in articular chondrocytes as well. Since
we were primarily interested in regulatory polymor-
phisms acting in cis, we screened our candidate genes
for allelic expression imbalances and promoter SNPs as-
sociated with the disease. Indeed, we found two genes
exerting allelic expression imbalances, which confirmed
the presence of cis-regulatory polymorphisms. In addi-
tion, we found, in the same two genes, 5′ SNPs that show
a statistically significant association with OA. We, there-
fore, consider our approach suitable to identify disease-
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Table 1
Primers for Amplification and Sequencing of the 5′
UTRs
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 2
Primers for Amplification and Sequencing of the 3′
UTRs
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
associated differential gene expression resulting from
regulatory gene polymorphisms.
Subjects and Methods
Study Population
For microarray analyses, six patients with knee OA awaiting
joint replacement surgery and six age-matched healthy controls
were analyzed. Whereas the controls were without any pre-
viously recorded joint complaints, the patients’ diagnosis of
OA was based on clinical evaluations, excluding metabolic
causes. All six patients with OA were recruited from the Char-
ite´ University Hospital in Berlin and were selected for com-
parable and low synovitis scores of the joints replaced. De-
termining the synovitis score included screening the tissues for
hyperplasia/enlargement of the synovial lining cell layer, ac-
tivation of resident cells/synovial stroma, and inflammatory
infiltrations.20
For the OA association study, SNP analysis was performed
on 171 patients undergoing joint replacement surgery and 182
healthy controls. Patients with OA as well as healthy controls
were of European white ethnicity. All patients fulfilled the cri-
teria of the American College of Rheumatology regarding OA
and were recruited from different hospitals within the Berlin
area. The mean age of the patients was 69.4  10.9 years,
with a male-to-female ratio of 1:2.9 and a hip-to-knee ratio
of 1:2.1. The mean age of the controls was 39.6  9.8 years,
with a male-to-female ratio of 1:1.9. The study was approved
by the local ethics committee, and informed consent was ob-
tained from all participants.
Microarray Analyses
Fifty milliliters of peripheral blood was obtained, and eryth-
rocytes were lysed using ammoniumchloride/Tris at 37C. Leu-
kocytes were then stained on ice with monoclonal antibodies
and Microbeads (Miltenyi Biotec). The CD15 cells were de-
pleted using automated separation with autoMACS (Miltenyi
Biotec). From the CD15 population, CD14 monocytes,
CD19 B cells, CD4 T helper cells, and CD8 cytotoxic T
cells were positive selected by fluorescence-activated cell sort-
ing, with use of the DiVantage (BD Biosciences) or the MoFlo
(DakoCytomation). The purities of the isolated cell fractions
were 198%. All samples were treated equally. Cells were lysed
directly after sorting, with the use of RLT lysis buffer (Qiagen)
containing b-mercaptoethanol. Total RNA was isolated using
the RNeasy Mini Kit (Qiagen) and was treated with DNAse
(RNase free DNase Set [Qiagen]), to remove genomic DNA.
Double-stranded cDNA was synthesized using SuperScript II
RNase H Reverse Transcriptase and the SuperScript II Kit
(Invitrogen) and was converted to Biotin-labeled cRNA via in
vitro transcription, with use of the BioArray HighYield Tran-
scription Labeling Kit (Enzo). The labeled cRNA was then
fragmented and hybridized to Affymetrix HG-U133A chips.
All preparation procedures and quality controls were per-
formed in accordance with the Affymetrix standard protocol.
Analyses of Allelic Imbalances
Genomic DNA was extracted from peripheral blood with
use of the Invisorb Blood Giga Kit (Invitek). Identification of
a SNP to be used as allelic marker within the transcribed region
was performed via PCR amplification and sequencing of the
UTRs. Information about 5′ and 3′ UTRs were derived from
public databases. UTRs were sequenced for their full lengths.
Primers were designed using the Primer3 software (Whitehead
Institute for Biomedical Research). The resulting 18–24mer
primers were suitable for amplifying and sequencing genomic
DNA fragments of ∼700 bp (for detailed primer sequence in-
formation, see tables 1 and 2). In cases where 3′ UTRs were
longer than 700 bp (PADI2 and VNN1 [MIM 603570]), mul-
tiple primer pairs were used. The PCR was performed using
the High Fidelity PCR Master (Roche), and the conditions were
30 cycles of 94C for 1 min, 55C–68C for 1 min, and 72C
for 1 min. Before sequencing, the PCR products were purified
using the Invisorb PCRapid Kit (Invitek), to remove primers
and PCR reagents.
Pyrosequencing technology (Biotage AB) was used to con-
firm differential gene expression at the allelic level. The cDNA
was synthesized using SuperScript II RNase H Reverse Tran-
scriptase (Invitrogen) and a mixture of random hexamere and
anchored oligo-dT primers. The RNA templates used were the
same as those used for microarray analysis. cDNA fragments
between 165 and 253 bp in length were PCR amplified using
the primers RHOB (MIM 165370) 5′ Bio-TGTGTGTCTG-
TTCGACTCCC-3′ (forward), RHOB 5′-GCAGTACCCGGG-
GTCTATGT-3′ (reverse), BLP2 5′ Bio-CAGGCCCACAGTA-
TTTCTTA-3′ (forward), BLP2 5′-GTGGGAGTGTTTCT-
GTTGTT-3′ (reverse), CIAS1 (MIM 606416) 5′ Bio-ACAGCT-
CTGTGATCCTTCCG-3′ (forward), CIAS1 5′-TACATGAG-
GTCACCAAGAGG-3′ (reverse), TXNDC3 (MIM 607421)
5′ Bio-ATGGAACTTCGCCGAGGTCA-3′ (forward), and
TXNDC3 5′-CGGTGTAGAACAGGGGTCAG-3′ (reverse),
and the PCR conditions were 45 cycles of 95C for 15 s, 50C–
60C for 30 s, and 72C for 15 s. For each gene and each
individual, four PCR samples were run in parallel. The PCR
products were then purified via the Invisorb PCRapid Kit (In-
vitek). The sequencing primers—RHOB 5′-CCGCTGGTGA-
AGG-3′, BLP2 5′-AGTTTTGCAGTGTAATACAT-3′, CIAS1
5′-TGAGGCGCTGTGAT-3′, and TXNDC3 5′-CCTCTAAG-
CTAGACTG-3′—were defined using the SNP Primer Design
software version 1.0.1 (Biotage AB). Before pyrosequencing
analysis, the biotinylated DNA strand was prepared using
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Table 3
Primers for Amplification and Sequencing of the
Promoter Regions
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 5
Summary of Microarrays Probed
Array Probe
1 Pool of CD4 cells from controls 1–6
2 CD4 cells from control 1
3 CD4 cells from control 2
4 CD4 cells from patient 1
5 CD4 cells from patient 2
6 CD4 cells from patient 3
7 CD4 cells from patient 4
8 CD4 cells from patient 5
9 CD4 cells from patient 6
10 Pool of CD8 cells from controls 1–5
11 CD8 cells from control 1
12 CD8 cells from control 2
13 Pool of CD8 cells from patients 1–3, 6
14 CD8 cells from patient 4
15 CD8 cells from patient 5
16 Pool of CD14 cells from controls 1–4, 6
17 CD14 cells from control 1
18 CD14 cells from control 2
19 CD14 cells from patient 1
20 CD14 cells from patient 4
21 CD14 cells from patient 5
22 CD14 cells from patient 6
23 Pool of CD19 cells from control 1–4
24 CD19 cells from control 2
25 Pool of CD19 cells from patients 1, 2, 4–6
26 CD19 cells from patient 3
Table 4
Primers for Analyzing SNP Associations via Allele-
Specific PCR
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
streptavidin-coated paramagnetic beads (Dynal), in accor-
dance with the manufacturer’s instructions. Measurements
were performed with the PSQ96 system (Biotage AB) and, in
the case of the CIAS1 gene, with the PSQ96HS system as well.
Each sample was run in quadruplicates (see above).
Genotyping
SNPs in the promoter regions and in the 3′ UTRs of the
genes were identified via PCR amplification and sequencing of
genomic DNA fragments. Promoter fragments were located 5′
of the transcription start site and were at least 500 bp long.
Information on the 3′ UTR was derived from public databases,
and 3′ UTRs were sequenced in full length. For detailed primer
information, see tables 2 and 3. To establish SNP associations,
171 patients and 182 controls were analyzed for the presence
of the promoter SNPs, excepting VNN1, via an allele-specific
PCR assay. Two different forward primers were designed with
the most 3′ base representing either the SNP or the wild-type
allele. Each forward primer was combined with a different
reverse primer, so that the PCR products differed in size. For
detailed primer information, see table 4. PCR was performed
using the PCR Master Mix (Promega), with 45 cycles of 94C
for 1 min, 62C–65C for 1 min, and 72C for 1 min. The
PCR products were analyzed on 2% agarose gels (GTQ, Roth).
Because the presence of the SNP at position 137 of the
VNN1 gene generates a recognition sequence for the endo-
nuclease MnlI, this SNP was genotyped via PCR and restriction
analysis. First, a 301-bp fragment was amplified using the
primers 5′-GCAGCCCTAGCGAACTAATG-3′ and 5′-CAGC-
TGCAGTGAAAGTGTCC-3′. PCR was performed using the
PCR Master Mix (Promega), with 30 cycles of 94C for 1 min,
60C for 1 min, and 72C for 1 min. PCR products were then
purified using the Invisorb PCRapid Kit (Invitek), before 4 ml
of the purified PCR product was digested using 10 units of
MnlI (MBI Fermentas) at 37C. After that, the DNA fragments
were analyzed on 2.5% agarose gels (GTQ, Roth).
Gene Expression Analyses in Articular Chondrocytes
Total RNA was isolated from the articular cartilage of pa-
tients with OA, via the guanidinium-isothiocyanate method.
Directly after joint replacement surgery, cartilage pieces were
obtained from the joint surfaces and were frozen in liquid
nitrogen. Then, the tissue was minced in liquid nitrogen using
a mortar and pestle, was resuspended in guanidinium-isothi-
ocyanate solution, and was homogenized using a syringe and
needle. After centrifugation, the supernatant was added to a
cesium chloride solution and was ultracentrifugated for 15–
20 h at 20,000 rpm. The RNA pellet was then resuspended
in diethyl pyrocarbonate–H2O, followed by the removal of
remaining proteins via a phenol/chloroform extraction. Finally,
the RNA was precipitated by the addition of yeast tRNA,
sodium acetate, and ethanol. cDNA synthesis was performed
as described above. Cartilage-specific gene expression was an-
alyzed via PCR amplification of cDNA, with use of the exon-
overlapping primers CIRBP (MIM 602649) 5′-CCGCTTGC-
GTCAGGGACCTG-3′ (forward), CIRBP 5′-CAGCCATTG-
GAAGGACGATCT-3′ (reverse), BLK (MIM 191305) 5′-GAA-
GTTGCTCGTTGTCGCT-3′ (forward), BLK 5′-TCATCCA-
GGTGTTCATC-3′ (reverse), DKFZP434O1427 5′-CGAGG-
CCAGAGAGAAAAGAC-3′ (forward), DKFZP434O1427
5 ′-CCAGCTACTCCCTTCTTTGG-3′ (reverse), FIZZ3/
RETN (MIM 605565) 5′-TGCAGGATGAAAGCTCTCTG-3′
(forward), FIZZ3/RETN 5′-TCTCCAGGTTTATTTCCAG-
CTC-3′ (reverse), VNN1 5′-ACGTGGCAATTTTGCTTTTC-
3′ (forward), VNN1 5′-TCACCAAGGTAACAGCAGGA-3′
(reverse), TXNDC3 (forward) 5′-GATGAGGCAGCTGAAG-
AACA-3′, and TXNDC3 (reverse) 5′-CACTAAAGAGAAAA-
ACAGGTTCACA-3′. The PCR conditions were 45 cycles of
94C for 1 min, 50C–55C for 1 min, and 72C for 1 min.
PCR amplification of b-actin–specific cDNA was used as a
positive control, with the primers 5′-CGGGAAATCGTGCG-
TGACAT-3′ (forward) and 5′-GAACTTTGGGGGATGCT-
CGC-3′ (reverse) and 20 cycles of 95C for 1 min, 65C for 2
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Figure 1 Combination of two software tools, which reduces the
number of differentially expressed candidate genes and lends more
weight to genes identified via two different methods. For each cell
type, lists of differentially expressed genes were compiled using DMT
and Genes@work (G@W), before intersections were formed. Black
numbers on the gray intersection indicate the results.
Table 6
Signal Values and Detection Calls Obtained from All
Gene Chips
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
min, and 72C for 1.5 min. PCR products were visualized via
agarose gel electrophoresis.
Bioinformatic and Statistical Analyses
Differences in mRNA expression levels between patients
with OA and healthy controls were assessed via Affymetrix
technology. For bioinformatics analyses, we combined two dif-
ferent software tools, the Affymetrix Data Mining Tool (DMT)
(v. 3.01) and Genes@work (v. October 2002). With use of the
DMT, comparisons were made between the signal log ratios
of individual chips, followed by two-sided Mann-Whitney
tests, to identify P values !.05. The only genes considered for
further analysis were those that showed a statistically signifi-
cant differential expression for 50% of the comparisons made
for CD4, CD8, and CD14 cells, and for 100% of the com-
parisons made for CD19 B cells. For the Genes@work anal-
ysis, we preselected “present” genes, performed pattern anal-
yses based on the signal values, and chose the pattern
containing the highest number of genes.
We assessed SNP associations by performing the x2 test,
including Yate’s continuity correction, based on the number
of alleles. P values were subsequently corrected in accordance
with Bonferroni. Testing for Hardy-Weinberg equilibrium
(HWE) was performed using the software Arlequin v2.0.
Results
Transcriptome Analysis of PBMC Reveals 26 Genes
Differentially Expressed in Patients with OA
To identify genes differentially expressed in patients
with OA and in healthy controls, we performed tran-
scriptome analyses on PBMC from six patients and six
age-matched controls. In detail, we isolated the CD4
and the CD8 T cells, the CD19 B cells, and the CD14
monocytes, to 198% purity each. From these 48 cell
populations, first-strand cRNA was synthesized. For the
controls, two individual cRNAs of each cell type and
cell type–specific pools were hybridized to HG-U133A
gene chips. For the patients, our goal was to hybridize
as many individual cRNAs as possible. However, since
some individual yields of mRNA were !5 mg, samples
had to be pooled. In total, 26 HG-U133A gene chips
were probed, as outlined in table 5.
For bioinformatic analyses, we combined two differ-
ent software programs, to generate lists of genes either
up- or down-regulated in patients with OA. We used
the DMT to calculate statistically significant expression
differences between patients and controls. The second
software program, Genes@work, was used to search for
similarities in gene expression among patients or con-
trols and to produce lists of genes for which the ex-
pression is similar among the patients but different from
the controls. Since both methods yield long lists of dif-
ferentially expressed genes, we formed the intersections
to lend more weight to genes identified via two different
methods. Figure 1 illustrates our results. In total, the
DMT revealed 210 differentially expressed genes for
the CD4, 484 for the CD8, 376 for the CD14, and 90
for the CD19 cells. In contrast, larger lists resulted
from the Genes@work analysis, yielding 555 differen-
tially expressed genes for the CD4, 2,329 for the CD8,
2,208 for the CD14, and 3,978 for the CD19 cells. The
intersections contain 86, 322, 181, and 86 genes,
respectively.
It was our goal to identify among these differentially
expressed genes those candidates that carry cis-regula-
tory gene polymorphisms. Assuming that cis-regulation
will be manifested in any cell type expressing the gene
of interest, we disregarded all the genes that, even though
present in all four cell types (see table 6), did not show
differential expression in all cell types. However, we did
allow for cell type–specific differential gene expression,
provided that these genes were expressed exclusively in
that particular cell type. To avoid mere inflammation
markers, we excluded those genes that also showed a
differential expression in PBMC from patients suffering
from chronic inflammatory joint diseases (A. Gruetzkau,
personal communication). We thus reduced the list of
candidate genes to the 26 listed in table 7. The signal
values for these 26 genes obtained from all gene chips
are listed in table 6. The mean fold changes were 1.37
for the CD19 B cells, 1.48 for the CD4 T helper cells,
1.53 for the CD8 cytotoxic T cells, and 1.72 for the
CD14 monocytes. The corresponding SDs were 0.73,
0.76, 1.06, and 0.57, respectively.
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Table 7
Differentially Expressed Genes in OA
Gene Protein
Expressed in CD4 cells only:
FBXL8 F-box and leucine-rich repeat protein 8
Expressed in CD8 cells only:
S100B S100 calcium-binding protein beta (neural)
Expressed in CD14 cells only:
ASGR2 Asialoglycoprotein receptor 2
CIAS1 Cold autoinflammatory syndrome 1
DYSF DYSFerlin, limb girdle muscular dystrophy 2B
FIZZ3/RETN Found in inflammatory zone 3
HM74 Putative chemokine receptor, GTP-binding protein
ICAM4 Intercellular adhesion molecule 4
IRAK3/IRAK-M Interleukin-1 receptor-associated kinase 3
KIAA0994/PADI2 Peptidyl arginine deiminase, type II
MGAM Maltase-glucoamylase (alpha-glucosidase)
TXNDC3 Thioredoxin domain containing 3
VNN1 Vanin 1, vascular non-inflammatory molecule
Expressed in CD19 cells only:
BLK B lymphoid tyrosine kinase
GH1 Growth hormone 1
Expressed in all four cell types:
RHOB RHOB, GTP-binding protein
BLP2 BBP-like protein 2
CIRBP Cold inducible RNA binding protein
DKFZP434O1427 Dactylidin
DUSP1 Dual specificity phosphatase 1
EIF4A1 Eukaryotic translation initiation factor 4A1
GPRK6 G-protein-coupled receptor kinase 6
H2AFO H2A histone family, member O
H3F3B H3 histone, family 3B (H3.3B)
SUI1 Putative translation initiation factor
TRC8 Patched-related protein translocated in renal cancer
Figure 2 outlines the experimental workflow pursued
to identify cis-regulation and disease association among
the 26 candidate genes. First, the genomic DNA of the
six patients and six controls were screened for allelic
differences in the 5′ and 3′ UTRs of all candidate genes.
Any SNP detected was considered for pyrosequencing,
which would reveal allelic imbalances and proof of cis-
regulation. Moreover, SNPs in the 5′ regions were di-
rectly analyzed for disease association, provided that
they showed a disparate distribution among the six pa-
tients and six controls that correlated with the differ-
ential expression seen on the gene chips. Disease asso-
ciation then prompted the analysis of gene expression
in articular chondrocytes, to strengthen a functional rel-
evance for the pathogenesis of OA. Genes carrying a
disease-associated SNP and expressed in chondrocytes
will be considered for further functional analysis. This
analysis could be overexpression or knockdown in chon-
drocytic cells, for the investigation of the genes’ impact
on apoptosis and cytokine response. Genes showing nei-
ther disparate promoter SNP distribution nor disease
association underwent no further analysis.
Analyses of Large Cohorts Reveal Disease Associations
for 5′ SNPs in the RHOB and TXNDC3 Genes
To identify new polymorphisms or to confirm previ-
ously published ones in the 5′ regions of our candidate
genes, we sequenced the genomic DNA from the six
patients and the six controls. In detail, we sequenced up
to 700 bp upstream of the respective transcriptional start
sites, and we also sequenced the 5′ UTRs if polymor-
phisms had been indicated. For seven genes, no poly-
morphisms were found. All the other 5′ SNPs were
tested, patient by patient, for a correlation with the re-
spective expression signals (see table 6). Figure 3 sum-
marizes the most promising results. Whereas, for
RHOB, BLK, CIRBP, and VNN1, an increased expres-
sion in the patients correlates with an increased fre-
quency of the minor promoter allele, the situation is
reversed for DKFZP434O1427. Here, the decreased
expression in the six patients is paralleled by a decreased
frequency of the minor promoter allele. For FIZZ3/
RETN, an increased expression in the patients corre-
lates with a decreased frequency of the minor allele.
TXNDC3 represents yet another situation, since the
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Figure 2 Workflow for the identification of cis-regulated and disease-associated genes among the 26 candidates. Our screening focuses
on allelic expression imbalances, disease-associated promoter polymorphisms, and expression in articular chondrocytes.
gene is switched off in the controls, as shown by mean
signal values of 79.6 in monocytes. However, in the pa-
tients, elevated signal values directly correlate with the
presence of the T allele at position 428. Signal values
are 96.5 and 99 for the CC, 178.6 for the CT, and 208.5
for the TT genotype (see table 6).
To screen a large cohort of patients with OA for an
association with any of these 5′ SNPs, we established
high-throughput PCR assays for the A/G SNP at position
165 of RHOB, for the C/T SNP at position 1218 of
BLK, for the G/A SNP at position 342 of CIRBP, for
the G/T SNP at position 81 of DKFZP434O1427, for
the C/G SNP at position 180 of FIZZ3/RETN, and
for the C/T SNP at position 428 of TXNDC3. For the
A/C SNP at position 137 of VNN1, a combined PCR/
restriction assay was established. A total of 171 pa-
tients and 182 controls were analyzed, and table 8 sum-
marizes the results. Allele distributions for all controls,
except for DKFZP434O1427, and for all patients, ex-
cept for RHOB and VNN1, conform to HWE. Whereas
no disease association was found for BLK, CIRBP,
DKFZP434O1427, FIZZ3/RETN, and VNN1, statis-
tically significant associations with OA resulted for the
165 promoter SNP of RHOB and for the 428 SNP of
TXNDC3, with corrected P values of .0007 each.
Gene Expression in Chondrocytes Supports a Role of
Candidate Genes in the Pathogenesis of OA
Because our initial transcriptome analysis was per-
formed on PBMC, formal proof of gene expression in
chondrocytes would lend weight to the role of the can-
didate genes in the pathogenesis of OA. To that extent,
we extracted mRNA from the cartilage of patients with
OA undergoing joint replacement surgery, transcribed
it into cDNA, and assayed for the presence of BLK-,
CIRBP-, DKFZP434O1427-, FIZZ3/RETN-, VNN1-,
and TXNDC3-specific transcripts. RHOB has been
shown elsewhere to be expressed in articular chondro-
cytes.21 Figure 4 summarizes the data. Whereas CIRBP,
DKFZP434O1427, and TXNDC3 are expressed abun-
dantly, BLK, FIZZ3/RETN, and VNN1 are expressed
at lower levels, and sequence-specific PCR products
could be visualized only in samples with high concen-
trations of cDNA. We thus conclude that our dif-
ferentially expressed candidate genes RHOB, BLK,
CIRBP, DKFZP434O1427, FIZZ3/RETN, VNN1, and
TXNDC3 are expressed in articular chondrocytes.
Allelic Expression Imbalances Confirm Cis-Regulation
for RHOB and TXNDC3
To provide direct proof for cis-regulation, we screened
for expression imbalances. We used the pyrosequencing
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Figure 3 Correlation between the presence of promoter SNPs
and expression signals, which hints at disease-associated regulatory
polymorphisms. Expression signals from CD14 monocytes (RHOB,
CIRBP, DKFZP434O1427, FIZZ3/RETN, and VNN1) and CD19
B cells (BLK) were averaged for the patients and were compared to
the pooled data from the controls in the left panels, detailing the
differential expression. The right panels compare the frequencies of
the minor alleles of promoter SNPs unevenly distributed between pa-
tients and controls. Whereas BLK is expressed exclusively in B cells
and FIZZ3/RETN and VNN1 in monocytes, RHOB, CIRBP, and
DKFZP434O1427 are expressed in all four cell types. The P values
of .012, .009, and .002 summarize their differential expression and
result from a Mann-Whitney test performed on the transcriptional
values from all cell types.
method, to quantify the amount of transcript arising
from each allele. The requirements for this method—a
suitable SNP allowing for the discrimination of both
alleles on the cDNA level and individuals heterozygous
for this particular SNP—were met by 16 of our can-
didate genes. However, because of homopolymeric
stretches close to the SNP, sequences leading to template
loops during the assay, absence of sufficient amounts of
mRNA, and very low frequency of that particular SNP
allowed for the successful analysis of RHOB, BLP2,
CIAS1, and TXNDC3 only. Table 9 lists the dbSNP
accession numbers of the SNPs used, their positions with
respect to the transcriptional start site, the heterozygous
donors, and the relative expressions arising from the sets
of two alleles. Whereas no allelic imbalances could be
observed for BLP2 and CIAS1, differential expression
on the allele level and, thus, cis-regulation is confirmed
for both RHOB and TXNDC3.
Absence of Allelic Imbalances and On/Off–Switching
of Genes Suggests Trans-Regulation
The absence of allelic imbalances for BLP2 and CIAS1
suggest trans-regulatory elements controlling the gene
expression (table 4). Alternative evidence for trans-
regulation is provided for FBXL8 (MIM 609077),
MGAM (MIM 154360), and TXNDC3. These genes
are switched off in the healthy donors, as indicated by
“absent” and “marginal” expression signals on the gene
chips. At the same time, they are switched on in the
patients (see table 6). Interestingly, TXNDC3 gene reg-
ulation occurs both in cis and in trans.
Discussion
Ever since differential gene expression has been impli-
cated in driving evolutionary processes,16 regulatory
gene polymorphisms have gained increasing attention.
Although the differential expression of genes allows for
a flexible response to a changing environment and may
thus be beneficial for the population as a whole, adverse
effects for the individual may occur.22 Indeed, regulatory
gene polymorphisms within the IL1 locus have been de-
scribed elsewhere to be associated with OA.18,19
Our approach to identify novel OA-associated regu-
latory gene polymorphisms is based on an initial tran-
scriptome analysis used to define genes that are differ-
entially expressed between patients and controls. We
chose PBMC for our transcriptome analysis for two rea-
sons: (1) Patient and control material is easily accessible
and can be obtained under identical conditions, and (2)
even though gene expression may be strictly cell type–
specific, numerous genes are expressed in a spatially less-
exquisite fashion. Indeed, data from our own lab and
the Affymetrix technical notes confirm that 40%–60%
of all genes represented on the HG-U133A gene are tran-
scribed in any tissue or cell type tested.23 The overlap of
genes simultaneously expressed in various cell types is
all the larger the closer the cells are related. Indeed, both
immune cells and chondrocytes are of mesodermal or-
igin, the development of the articular cartilage/bone sys-
tem and of the adaptive immune system is phylogenet-
ically tightly linked, and both systems use the same
Table 8
5′ SNPs in the RHOB and TXNDC3 Genes Show Association with OA
Gene Position
dbSNP
Accession
Number SNP
Allele Distribution
(Controls)
HWE P
Value (Controls)
Allele Distribution
(Patients)
HWE P
Value (Patients)
SNP
Association
P Value
BLK 1218 rs27366344 C/T 84.2/11.1 .491 85.6/14.4 .294 .243
CIRBP 342 rs12980707 G/A 85.4/14.4 .124 80.3/19.7 .572 .1058
DKFZP434O1427 81 rs877661 G/T 77.7/22.3 .025 74.2/25.8 .46 .312
VNN1 137 rs4897612 A/C 70.5/29.5 .863 69.2/30.8 .011 .7882
FIZZ3/RETN 180 rs1862513 C/G 68.9/31.1 .699 75.9/24.1 .786 .3353a
RHOB 165 rs49846015 A/G 76.1/23.9 .569 60.8/39.2 .005 .0007a
TXNDC3 428 rs4720262 C/T 86.6/13.4 .251 74.1/25.9 .149 .0007a
a P values were corrected according to Bonferroni; P values !.05 show deviation from HWE.
Figure 4 Gene expression in chondrocytes supporting a role for candidate genes in the pathogenesis of OA. RNA isolated from the
cartilage of patients with OA undergoing joint replacement surgery was transcribed into cDNA and was assayed for the presence of specific
transcripts of BLK, CIRBP, DKFZP434O1427, FIZZ3/RETN, VNN1, and TXNDC3. The comparison to b-actin indicates the use of unequal
amounts of template cDNA for the three patients. Size markers are indicated on the left of each panel, and the sizes of the specific PCR products
are given on the right. MW p molecular weight.
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Table 9
RHOB and TXNDC3 Show Allelic Imbalances
Gene and Donor
Allelic
Expressiona
dbSNP
Accession Number Position
RHOB: rs1062292 2749
Control 1 G 46.6/53.4 T
Control 4 G 35.8/64.2 T
Patient 3 G 27.4/72.6 T
Patient 6 G 49.7/50.3 T
BLP2: rs708394 10401
Control 3 T 47.0/53.0 C
Control 4 T 49.8/50.2 C
Patient 4 T 48.4/51.7 C
CIAS1: rs10754558 30685
Control 1 C 50.3/49.7 G
Control 2 C 50.1/49.9 G
Control 3 C 52.6/47.4 G
Patient 1 C 46.5/53.5 G
TXNDC3: rs4720262 428
Control 1 G 48.1/51.9 A
Patient 6 G 33.3/66.7 A
a Allele 1 percentage/allele 2 percentage.
cytokines and growth factors as messenger molecules.2
Our approach is, therefore, likely to identify genes as-
sociated with the systemic character of OA but is bound
to miss those expressed in a cartilage-specific manner.
Indeed, IL-1b was upregulated in some patients’ mono-
cytes; however, the difference between patients and con-
trols was not significant enough to pass our stringent
bioinformatics analyses.
We identified 26 genes that are differentially expressed
between patients with OA and controls. Whereas RHOB
and S100B (MIM 176990) have been directly linked to
OA before,21,24 GH1 (MIM 139250) has been shown to
be involved in chondrocyte differentiation in the growth
plate and to be associated with short stature (SS [MIM
604271]).25 Other genes—among them RHOB, BLP2,
CIAS1, DUSP1 (MIM 600714), DYSF (MIM 603009),
and S100B—have been implicated in apoptosis and reg-
ulation of cell cycle and repair.21,26–30 A link to the OA
characteristic of imbalance of cartilage degeneration and
regeneration is, therefore, plausible. Other feasible can-
didates are transcription and translation factors like
DKFZP434O1427, FBXL8, EIF4A1 (MIM 602641),
and SUI1,31–34 even though their specific targets need to
be identified before the link to OA can directly be ex-
plained. Another candidate, VNN1, is a glycosyl-phos-
phatidylinositol–anchored cell surface molecule, which
has, so far, been implicated in the homing of T-cell pro-
genitors to the thymus and in sexual development in the
mouse.35,36 Interestingly, in mouse testis, VNN1 is reg-
ulated by Sox-9, a transcription factor involved in chon-
drocytic differentiation during development and still ex-
pressed in articular chondrocytes.37,38 An additional
interesting candidate is TXNDC3, which shows cis-reg-
ulation and carries a 5′ SNP with a statistically significant
association with OA. Likewise, the thioredoxin protein
NM23-H8 encoded by TXNDC3 has been described
elsewhere to be expressed in testis.39,40 Here, we add the
expression in monocytes and chondrocytes; however, the
exact role of TXNDC3 for the pathogenesis of OA needs
to be further investigated.
To identify regulatory gene polymorphisms respon-
sible for the differential expression, we pursued two dif-
ferent routes. The first one focused directly on poly-
morphisms in the 5′ regions of the genes, which were
screened (1) for a disparate distribution among patients
and controls and (2) for a correlation between the SNP
haplotype and the signal value. Even though the analy-
sis of six patients and six controls uses too few subjects
for any firm conclusions to be drawn, we demanded an
obvious correlation between the presence of a regula-
tory gene polymorphism and the differential expression
documented in signal values. This correlation is graph-
ically documented for six genes and their SNPs in figure
3. These six SNPs and the 5′ SNP of TXNDC3 were
subsequently analyzed for disease associations, with the
use of larger cohorts. Interestingly, except for the
DKFZP434O1427 gene, the tendencies for the rare al-
leles found in the six patients and six controls initially
analyzed were again reflected in the larger cohorts. The
5′ SNP in the TXNDC3 gene is located in the second
exon, which is noncoding, and the direct correlation of
the T allele with an elevated expression hints either at
a tight linkage disequilibrium with a regulatory SNP or
at some regulatory function. The latter is supported by
the observation that TXNDC3 transcripts seem to be
alternatively spliced in monocytes and chondrocytes,
with the chondrocyte transcripts lacking exon 2 (data
not shown). In total, we identified two OA-associated
polymorphisms in the genes encoding RHOB and
TXNDC3. And, whereas no direct statistical significance
could be observed for the other five genes tested, the
genotype distributions for VNN1 and DKFZP434O1427
and the resulting differences in the Hardy-Weinberg dis-
equilibria between patients and controls suggest that the
analysis of larger cohorts may yield more disease asso-
ciations. The second route pursued the identification of
OA-associated regulatory gene polymorphisms and fo-
cused on differential expression detectable on the allele
level. To that end, we performed pyrosequencing anal-
yses and used SNPs in the transcribed regions of the
genes, to differentiate both alleles. We did not, however,
assume that a SNP in the 3′ UTR might be the regulatory
polymorphism itself, nor do we know about any linkage
disequilibrium with a 5′ regulatory SNP. Any negative
result could consequently be a false negative one. Even
though pyrosequencing is a very powerful method, there
are numerous technical restrictions, and, among our 26
candidates, pyrosequencing analysis could be performed
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for 4 genes only. Two of them, RHOB and TXNDC3,
showed allelic imbalances and, thus, direct proof of a
cis-regulated gene expression. In contrast, BLP2 and
CIAS1 showed a balanced expression hinting at trans-
regulation. It should be mentioned, though, that bal-
anced expression per se does not exclude the possibility
of cis-regulation and differences in allelic expression in
individuals not tested here. Supporting trans-regulation
for BLP2 and CIAS1 are the lack of suggestive 5′ poly-
morphisms in both genes, yet it was beyond the scope
of this article to scan more distantly for SNPs. Also
beyond scope was the follow up on trans-regulated gene
expression.
In summary, we identified 26 genes that are differ-
entially expressed in OA patients and that may contrib-
ute to the pathogenesis of the disease. We confirmed
allelic imbalances and, hence, a cis-regulated gene ex-
pression for TXNDC3 and RHOB. For both, 5′ SNPs
that show a statistically significant association with OA
have been identified. Whether these SNPs are true reg-
ulatory gene polymorphisms needs to be confirmed with
molecular methods. The elucidation of the specific func-
tion of the various genes in the context of OA will help
the understanding of the pathogenesis of the disease and
will hint at novel therapeutical approaches.
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